A patient with severe aplastic anemia underwent a matched unrelated bone marrow transplant, following which he developed a complex autoimmune syndrome. This featured transverse myelitis, immune mediated Coombs positive hemolytic anemia and immune thrombocytopenia (Evans syndrome), pulmonary infiltrates, eosinophilia, muscle pains and cramps and lichenoid dermatitis all of which may represent manifestations of graft-versus-host disease as they showed response to immunosuppression. Thus, although immune-mediated cytopenias after an allogeneic bone marrow transplant are rare, they should be considered as a possible cause of cytopenia in post-transplant patients. Bone Marrow Transplantation (2000) 26, 1225-1228.
Immune dysregulation is a well recognized consequence of allogeneic bone marrow transplant (BMT) . 1 This may manifest as classic graft-versus-host disease (GVHD), or development of antibodies against epidermis, smooth muscle, nuclei, mature hematopoietic cells etc. 2 Immune thrombocytopenia is a known complication after BMT, and autoimmune neutropenia has been described, [3] [4] [5] as have cases of immune-mediated hemolytic anemia (HA). 6, 7 Most of the cases of immune-mediated hemolysis are alloimmune in origin due to either major or minor blood group incompatibility between the donor and the recipient. 7 Autoimmune hemolytic anemia (AIHA) is rare but represents a serious complication of allogeneic BMT. We report a patient who developed, in addition to immune-mediated HA, two rare manifestations attributed to GVHD.
Case report
In November 1995 a 40-year-old white male with no past medical history was diagnosed with drug-induced hepatitis on liver biopsy, after two months of pravastatin therapy. His total serum bilirubin reached 43 mg/dl and transaminases 2000 U/l. The hepatitis resolved spontaneously over a 3-month period, after which his blood counts began to decline. Sequential bone marrow (BM) and peripheral blood examinations over the next 3 months confirmed a diagnosis of severe aplastic anemia (SAA) in June 1996. BM cytogenetic examination was normal. Work-up for Fanconi's anemia and CD55 and CD59 for PNH were negative.
In September 1996, treatment was initiated with CsA, ATG and prednisone, a second course of which was given in November 1996 with transfusion support. Between September 1996 and February 1997 he received 15 U PRBC and 23 U platelets. CsA was discontinued in February 1997 for lack of response.
In March 1997, a BMT was performed using an unrelated A, B, DR and DQ molecularly matched donor. Conditioning was carried out with TLI 900 cGy, cyclophosphamide 50 mg/kg/day for 4 days, and ATG 20 mg/kg/day for 4 days. The donor blood group was O-positive and the recipient's blood group was A-positive pretransplant. There were two cytogenetic polymorphic markers on the donor cells, 14s+ and 21s+, that differentiated them from host cells. The patient engrafted WBC and platelets on day +15.
On day +39, CBC showed Hb 11.6 g/dl, WBC 23.9 × 10 9 /l, platelets 230 × 10 9 /l, however his red blood cell type remained A positive, consistent with recipient phenotype. He had grade II skin GVHD while on prophylaxis with cyclosporin and prednisone, which resolved. The immunosuppression was subsequently tapered. Bone marrow cytogenetics done on days +21 and +95 showed complete donor engraftment as evidenced by lack of 14s+ and 21s+, characteristic of host cells.
In September 1997, 6. months after BMT while on maintenance CsA and prednisone, he developed ataxia, numbness and paresthesias below the waist, and motor weakness of the lower extremities. An MRI showed white matter changes of the spine from C6-T4. CSF examination showed increased protein of 88 mg/dl and a WBC of 5. CT scans of chest, abdomen and pelvis were negative. CMV titers of patient and donor were negative pretransplant and there was no evidence of CMV reactivation in the recipient on CMV culture and CMV DNA hybridization post transplant. A diagnosis of transverse myelitis of unknown etiology was made. This neurological syndrome improved with steroids and resolved by October 1997. On repeat MRI of the spine, the white matter lesions had resolved. At that time, Hb was 12.3 g/dl, WBC 4.6 × 10 9 /l and platelets 151 × 10 9 /l. On 29 October 1997 (day +223), while steroids were being tapered, the patient developed anemia and thrombocytopenia. A CBC showed: WBC 9.2 × 10 9 /l, Hb 6.1 g/dl, platelets 50 × 10 9 /l and reticulocytes 20%. A bone marrow aspirate showed a hypercellular marrow with a decreased M:E ratio and increased number of megakaryocytes consistent with peripheral destruction of red cells and platelets. Bone marrow cytogenetics showed 2/30 (6.6%) host metaphase cells. The patient complained of recurrent numbness over the arms and hands. The total bilirubin was 4 mg/dl and LDH 500 U/l. The direct antiglobulin test (DAT) was positive for IgG, and the indirect antiglobulin test and eluate studies identified a warm autoantibody reactive against all tested cells, without specificity. The patient's blood group by red cell and isohemagglutinin typing was A positive (recipient phenotype). Red cells were A+, D was 4+ by front typing. By back typing, A 1 antibodies were negative and anti-B was 2+. Dexamethasone 4 mg three times daily and 6 units of type 'O' red cells were given over 48 h. The platelet count normalized and the Hb stabilized at 9 g/dl. However, mild ongoing hemolysis persisted although the paresthesias improved.
In January 1998, while on prednisone 10 mg every other day, the LDH increased and severe hemolysis recurred with the DAT strongly positive for IgG. The patient responded again to high-dose steroids. His Hb remained at 8 g/dl on prednisone 50 mg daily. By March 1998 there was continued evidence of mild hemolysis and he underwent splenectomy on day 344. Steroid taper was resumed. The Hb improved to 12.5 g/dl and platelets to 537 × 10 9 /l. In April 1998 (day +395) his Hb was 11.7 g/dl and platelets 57 × 10 9 /l on prednisone 25 mg a day. A bone marrow done on this day documented increased megakaryocytes and a diagnosis of Evans syndrome was made. Indirect antiplatelet antibodies were negative at this time and the direct test was not informative. BM cytogenetics showed 2/33 (6%) host cells. Steroids were increased again but hemolysis persisted and the Hb declined to 5.3 g/dl. The blood group was A-positive by front typing. However anti-A and anti-B isohemagglutinins were present. The direct Coombs test was negative and indirect Coombs test was positive, consistent with a mixed patient and donor phenotype, suggesting red cell chimerism. Studies to determine the degree of chimerism by VNTR analysis of peripheral blood failed because the patient and his donor were genotypically identical at D1S80, APOB, 33.6, D17S5, CFS1PO, TPOX and THO1 loci. The patient received no transfusions at this time but was treated with plasmapheresis, cytoxan, and erythropoietin and Hb rose to 11.2 g/dl and platelets to 524 × 10 9 /l by day +432.
Between June 1998 and September 1998, the Hb improved to 15.7 g/dl and erythropoietin was stopped. The prednisone was tapered to 5 mg daily, and on day +649 the WBC was 24.3 × 10 9 /l, platelets 609 × 10 9 /l and Hb 15.9 g/dl. Differential showed 35% eosinophils, 40% segs, 4% bands. The alkaline phosphatase increased from 152 U/l to 338 U/l, GGT from 84 U/l to 207 U/l. A CT scan of the chest, abdomen and pelvis in January 1999 showed scattered patchy infiltrates in both lungs. Bronchoscopy and BAL cultures were negative. Transbronchial biopsy only showed severe inflammation and focal fibrosis, negative for tumor or granulomata. Prednisone was empirically started at 20 mg a day. Two weeks later (day +680) the WBC was 10.9 × 10 9 /l, Hb 17 g/dl and platelets 433 × 10 9 /l. The steroids were tapered. Repeat CT of the chest in February 1999 showed improvement of the infiltrates.
In April 1999 (day +761) he started complaining of muscle pain and joint stiffness with decreased range of motion and normal CPK while on 10 mg/day of steroids. Work-up for rheumatological disorders was negative. Thalidomide treatment was started on day +909. On day +965 he developed grade II GVHD of skin. A skin biopsy showed lichenoid dermatitis consistent with GVHD. It improved on increasing the steroids to 20 mg/day and starting PUVA therapy. His muscles felt firm and indurated and he started developing severe muscle cramps. Thalidomide was stopped due to peripheral neuropathy. The patient is currently on 60 mg/day of prednisone. Figure 1 shows Hb and platelet counts in relation to time after transplant and timing of steroid pulses.
Discussion
Autoimmune HA affects 0.001% of the general population. 7 A higher incidence of 3-5% has been described in one study in T cell-depleted allograft recipients especially for those who survived 6 months post BMT. 7 Autoimmune HA has been seen to co-exist with peripheral blood esinophilia in a patient with GVHD in one report, 8 with sensorimotor peripheral neuropathy that responded to steroids in another study 4 and with autoimmune thyroiditis and transverse myelitis as a part of a generalized autoimmune syndrome in yet another case report. 7 The patient that we report also developed a transverse myelitis responsive to steroids 9 months after allogeneic BMT followed by immunemediated HA. Evidence of immune-mediated HA in our patient includes (1) the positive direct Coombs test; (2) positive indirect Coombs test with serum antibody reacting with broad specificity; (3) positive red cell eluate with broad specificity; and (4) clinical evidence of significant hemolytic anemia. This along with the immune thrombocytopenia led us to believe that the patient had Evans syndrome. The significant eosinophilia seen in our patient and in others previously 3, 8 suggests that this is an uncommon manifestation of chronic GVHD.
Development of antibodies against peripheral RBC in the post-transplant patient may be due to persistence of residual sensitized host cells or passively transfused antibodies in the early post transplant period. However, in our patient, chimerism studies showed 100% donor cells in the first 222 days. Also, residual host immunity persists for approxi- mately 4 months post transplant in most cases and is unlikely to account for the immune-mediated HA seen 9 months after BMT except when residual recipient lymphocytes are present. Alternatively, partial chimerism may result in the development of donor vs recipient red blood cell alloreactivity. Finally, immune dysregulation of the recipient immune system may occur due to the BMT and lead to true autoimmunity. At the present time the patient's absolute total T cell count is 367/mm 3 (normal range 750-2500), demonstrating persistent T cell deficiency. However, because he remains on steroids this data should be interpreted with caution.
In our patient, BM cytogenetics showed 2/30 host metaphases indicating that the immune-mediated HA may be due to antibodies derived from host or donor lymphocytes and recognizing donor or recipient RBC antigens. The existence of A-type red cells during severe hemolysis may reflect the emergence of a residual host clone under stress hematopoiesis. There are a number of phenomena in our patient that seem to be immune in nature. First, the symptoms of transverse myelitis, 6. months after BMT which improved and subsequently resolved with steroids. Second, Evans syndrome with Coombs positive anemia and thrombocytopenia coincided with tapering of steroids. The patient's course over the next several months was notable for waxing and waning of blood counts correlating with the amount of immunosuppression used, again suggesting a marked immune component. The platelets followed a similar pattern with decreasing platelets corresponding to tapering of immunosuppression and recovery with increasing immunosuppression, again suggesting an immunemediated mechanism. The third component was a pulmonBone Marrow Transplantation ary syndrome with eosinophilia which responded to steroids.
Most recently, the patient has developed myositis and chronic GVHD of the skin, further suggesting that all these features may be varying manifestations of GVHD.
The neurological and pulmonary complications that this patient displayed during his post-transplant course are more likely to represent rare manifestations of GVHD. The response to increased immunosuppression and the association with eosinophilia are strong indicators of that etiology. Autoimmune HA, pulmonary infiltrates and transverse myelitis have been previously associated with allogeneic BMT thus raising the possibility that these tissues share antigenic determinants, this having been previously observed in the case of red cells and neural tissue. 9 The question then arises that if these immune-mediated complications relate to residual host cells, does the degree of mixed chimerism influence the frequency with which one would expect to see such complications and should one expect to see more of these as mini-transplants come into vogue.
In summary, although autoimmune cytopenias after an allogeneic BMT are rare, they should be considered as a possible cause of cytopenia in the post-transplant setting.
